BMS to reveal broad spectrum cancer data

Erbitux, Sprycel and Ixempra are three of the drugs Bristol-Myers Squibb (BMS) will be highlighting at the American Society of Clinical Oncology annual meeting, its has announced.

In addition, representatives will focus on data on investigational compounds ipilimumab, brivanib and CT-322 in relation to broad spectrum of cancers, including colorectal, head and neck, leukaemia, lung, breast, melanoma and prostate.

Elliott Sigal, research and development (R&D) executive vice-president, chief scientific officer and president, suggested BMS is leading the way in the fight against cancer.

“Our robust oncology pipeline holds the promise and potential of delivering additional treatment options for physicians and patients,” he added.

The data on non-small cell lung cancer potential treatment Erbitux will be presented alongside BMS’s partners Merck and ImClone Systems.

Medarex will join BMS in presenting data on the investigational immunotherapy ipilimumab.

Last October Science magazine ranked BMS as one of the top 20 international employers, for the second consecutive year, for, among other things, undertaking “important, quality research”, BMS noted on its website.